miR-203 Expression in Exfoliated Cells of Tongue Coating Represents a Sensitive and Specific Biomarker of Gastroesophageal Reflux Disease

Xiuli Yan, 1 Shengliang Zhu, 1 and Hui Zhang 2

1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Hongkou, Shanghai 200437, China
2 Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Pudong, Shanghai 201203, China

Correspondence should be addressed to Shengliang Zhu; zhushengliang999@163.com and Hui Zhang; zhanghuiman@126.com

Received 19 May 2016; Accepted 26 July 2016

Academic Editor: Tetsuro Setoyama

Background and Aim. MicroRNAs (miRNAs) have been implicated in the pathophysiology of numerous human diseases including gastroesophageal reflux disease (GERD). The objective of this study was to investigate the miRNA expression of exfoliated cells of the tongue in patients with GERD versus healthy controls (Ctrls). Methods. Using quantitative reverse-transcription PCR (qRT-PCR), expression levels of six candidate miRNAs (miR-143, miR-145, miR-192, miR-194, miR-203, and miR-205) were examined across a discovery cohort of patients with GERD (n = 24) versus Ctrls (n = 24). These findings were confirmed across a validation cohort (GERD, n = 142; Ctrls, n = 48). Differences in miRNA expression levels were evaluated using the Mann-Whitney U test while the specificity and sensitivity were obtained using receiver-operator characteristic (ROC) curves.

Results. miR-203 was significantly downregulated in GERD patients as compared to Ctrls (P < 0.0001) with ROC curve of 0.94 (95% CI: 0.90–0.97). The sensitivity and the specificity of miR-203 were 91.7% and 87.3%, respectively, in the GERD and Ctrls. These results suggest that miR-203 may be a useful diagnostic marker for discriminating GERD from Ctrls. Conclusions. miR-203 testing may assist in the diagnosis of patients with symptoms suggestive of GERD.

1. Introduction

Gastroesophageal reflux disease (GERD) is a chronic disease of mucosal damage caused by the backflow of stomach acid into the esophagus. GERD is a condition that knows no boundaries, affecting 5–7% of the population worldwide. It has been shown to have a significant negative impact on the quality of life of those affected, disrupting their daily activities [1]. Diagnostic methods to confirm or reject GERD include empirical PPI treatment, GERD specific questionnaires, endoscopy, and ambulatory reflux monitoring. Unfortunately, these approaches do not achieve high sensitivity and specificity, particularly in patients with nonerosive reflux disease (NERD), and some of them are invasive and expensive [2].
evaluation of the tongue coating is a relatively noninvasive, simple, safe approach that may yield important contributions to clinical diagnoses.

MicroRNAs (miRNAs) are evolutionarily conserved, small (typically ~22 nucleotides long) RNA molecules that modulate the expression levels of target genes and are thus actively involved in a wide range of physiologic and pathologic processes. As such, numerous studies have highlighted the use of miRNAs as highly sensitive and specific biomarkers for the diagnosis of several diseases [6–9]. In previous studies, a link between gastroesophageal disease and changes in miRNA expression levels was established [10–12]. Specifically, Wijnhoven et al. [10] have shown that miR-203 and miR-205 are high in normal squamous epithelium and low in columnar epithelia, while miR-21, miR-143, miR-145, miR-194, and miR-215 are significantly upregulated in columnar tissues compared with normal squamous epithelium. Smith et al. [11] demonstrated that miR-143, miR-145, and miR-205 expression levels appear to be elevated in oesophageal squamous mucosa of individuals with ulcerative esophagitis, while Bus et al. [12] reported that miR-143, miR-145, miR-192, and miR-194 were upregulated in esophageal epithelial cells upon acidic bile salt stimulation. Importantly, the miRNA expression in the tongue coating of patients with GERD has not yet been evaluated.

The objective of this study was to investigate the differences of miRNAs expression in exfoliated cells of the tongue coating between patients with GERD and healthy controls (Ctrl). We evaluated the expression levels of miR-143, miR-145, miR-192, miR-194, miR-203, and miR-205 in exfoliated cells of the tongue coating in patients with GERD and Ctrl across a discovery cohort of 48 specimens. We validated our findings across an independent cohort, thereby confirming that miR-203 was significantly downregulated in GERD as compared to Ctrl levels. Our study demonstrated that miR-203 in exfoliated cells of the tongue coating can be used as a potential noninvasive biomarker for the diagnosis of GERD.

### Table 1: Clinical characteristics of GERD and healthy control participants.

| Parameters          | GERD                  | Healthy          |
|---------------------|-----------------------|------------------|
| Individuals (n)     | 166                   | 72               |
| Grade A (n = 103), grade B (n = 42), grade C (n = 11), grade D (n = 6), Barrett's oesophagus (BE) (n = 4) | | |
| Male                | 63                    | 30               |
| Female              | 103                   | 42               |
| Age (years)         | 59.28 ± 10.5          | 58.48 ± 5.98     |

Ages are given as mean ± S.D.

2. Methods

2.1. Study Subjects and Clinical Parameters. From January 2014 to March 2015, 166 patients with GERD were recruited from Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. All patients underwent an open-access transoral upper gastrointestinal endoscopy, and those who had typical symptoms (heartburn and regurgitation) or abnormal acid contact time detected at ambulatory esophageal pH testing were considered for inclusion in the study. Exclusion criteria were as follows: (1) GERD combined with other structural gastrointestinal disorders, such as peptic ulcer disease or esophageal or gastric malignancy; (2) prior gastric surgery; and (3) pregnancy. Seventy-two (n = 72) healthy normal volunteers who had a physical examination (at Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine) and health history including question about drug use were recruited and used to represent the normal control group. Only those evaluations (history, physical examinations, and laboratory tests) needed to determine eligibility for a particular study will be done. The clinical parameters of these patients were shown in Table 1. This study was approved by the Institutional Review Board of Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Informed consent was signed by each of the participants, and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki (1964).

2.2. Tongue Coating Samples Collection and RNA Isolation. To avoid influence of other possible confounding factors, tongue coating samples were collected in patients with newly diagnosed GERD or first visit. All tongue coatings of GERD patients and healthy volunteers were sampled in the morning prior to breakfast. All participants were required to rinse their mouth before sampling. All tongue coatings were stored at ~80°C. RNA was isolated using a mirVana PARIS kit (Ambion, Austin, TX, USA) according to the manufacturer’s protocol followed by the treatment of RNase-free DNase I (Promega, Madison, WI, USA) to eliminate DNA contamination.

2.3. Quantification of miRNAs. Quantification of miRNAs was based on the stem-loop RT-PCR method. First, a miRNA-specific stem-loop RT primer is hybridized to the miRNA and then reverse transcribed. Next, the RT product is amplified and monitored in real-time using a miRNA-specific forward primer and the universal reverse primer (Table 2). PCR was performed with SYBR Green PCR Master Mixture (TOYOBO, LTD, Japan) according to the manufacturer’s instructions by using ABI StepOnePlus real-time PCR system. The specificity of each PCR product was validated by performing melting curve analysis at the end of PCR cycles. All samples were analyzed in triplicate and
Table 2: Primer sequences for qRT-PCR.

| miRNA   | Forward Primer                  | Reverse Primer                  |
|---------|---------------------------------|---------------------------------|
| miR-143-FP | ACACCCAGCTGGGTTGAGAAGCAGTCG    | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA |
| miR-143-RP | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA | ACACCCAGCTGGGTTGAGAAGCAGTCG |
| miR-145-FP | ACACCCAGCTGGGTTGAGAAGCAGTCG    | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA |
| miR-145-RP | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA | ACACCCAGCTGGGTTGAGAAGCAGTCG |
| miR-192-FP | ACACCCAGCTGGGTTGAGAAGCAGTCG    | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA |
| miR-192-RP | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA | ACACCCAGCTGGGTTGAGAAGCAGTCG |
| miR-194-FP | ACACCCAGCTGGGTTGAGAAGCAGTCG    | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA |
| miR-194-RP | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA | ACACCCAGCTGGGTTGAGAAGCAGTCG |
| miR-203-FP | ACACCCAGCTGGGTTGAGAAGCAGTCG    | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA |
| miR-203-RP | CTCAACTGGTGTCGTGGAGTCAATTCAGGTGAGCTACA | ACACCCAGCTGGGTTGAGAAGCAGTCG |
| U6-FP    | CTCGCTTCGGCAGCACA               | AACGCTTCAGCAATTTCGCTGTTGAGAGTCAATTCAGGTGAGCTACA |
| U6-RP    | AACGCTTCAGCAATTTCGCTGTTGAGAGTCAATTCAGGTGAGCTACA | CTCGCTTCGGCAGCACA |

the cycle threshold (Ct) was defined as the number of cycles required for the fluorescent signal to reach the threshold. The levels of miRNAs were calculated using the formula $2^{-\Delta Ct}$, where $\Delta Ct = Ct$ of internal reference $-Ct$ of target miRNA. U6 RNA was used as a miRNA internal control. Data obtained by real-time PCR were translated in log 10 (relative level).

2.4. Statistical Analysis. Comparisons between groups were analyzed using Mann-Whitney U test. Receiver-operator characteristic (ROC) curves were established to evaluate the difference in the levels of miRNAs among GERD patients and Ctrls. All tests were two-tailed and $P < 0.05$ was considered statistically significant.

3. Results

3.1. Description and Clinical Features of the Patient Cohorts. A total of 166 GERD patients and 72 healthy controls were included in this study. Patient demographics are shown in Table 1. All patients were grouped according to the LA GEDR classification. 103 participants were classified as grade A (62%), grade B ($n = 42$, 25%), grade C ($n = 11$, 7%), and grade D ($n = 6$, 4%). Only 4 study subjects were diagnosed with Barrett esophagus.

3.2. miRNAs Expression in Exfoliated Cells of the Tongue Coating of GERD and Ctrls. To assess differential expression of miRNAs in exfoliated cells of the tongue coating between GERD ($n = 24$) and Ctrls ($n = 24$), 6 candidate miRNAs (miR-143, miR-145, miR-192, miR-194, miR-203, and miR-205) were selected. In this manner, we found that miRNAs can be found in exfoliated cells of the tongue coating in Ctrls and patients with GERD. Meanwhile, we observed a statistically significant downregulation of miR-203 in GERD as compared to Ctrls ($P < 0.0001$) (Figure 1).

3.3. miR-203 Level in Exfoliated Cells of the Tongue Coating Was Downregulated in Patients with GERD. To confirm the specificity and accuracy of our findings we pursued additional qRT-PCR testing across a validation cohort composed of 142 GERD and 48 Ctrls individuals. In keeping with our initial observation, miR-203 was significantly downregulated in GERD specimens as compared to those levels in Ctrls ($P < 0.0001$) (Figure 2).

3.4. miR-203 Level in Exfoliated Cells of the Tongue Coating Can Be Used to Distinguish GERD Patients from Ctrls. Comparing GERD subjects with Ctrls, ROC curve areas of miR-203 were found to be 0.94 (95% CI: 0.90–0.97) (Figure 3). The sensitivity and specificity of miR-203 were 91.7% and 87.3%, respectively, in the GERD subjects and Ctrls. These results suggest that miR-203 can be used to discriminate individuals with GERD from Ctrls.

4. Discussion

The tongue is part of digestive system and acts as a very good mirror. The tongue has a coating, which represents the state of digestive function in our body. The tongue coating has been shown to play an important role in reflecting the occurrence, development, and prognosis of numerous diseases [2–4]. The normal tongue coating consists of a thin, white film on the surface of the tongue. In the present study, we demonstrated that the tongue coating in patients with GERD was different from the expected color and pattern observed in Ctrls. Patients with GERD exhibited a yellow tongue coating coloring and frequently displayed eroded tongue coating.

Interestingly, the stability of miRNAs has been readily described not only in tissues or cultured cell lines, but also in human body fluid (plasma, serum, saliva, and urine). Moreover, the expression of miRNA species has been recently shown to correlate with different physiological stages and pathological conditions. As such, some disease-specific profiles can provide crucial diagnostic and prognostic information, highlighting the necessity to exploit miRNAs for possible use as biomarkers [6–9].
Several recent studies have documented the aberrant expression of miRNAs in the pathogenesis of GERD. The expressions of miR-143, miR-145, and miR-205 were significantly higher in oesophageal squamous mucosa from subjects with GERD compared to squamous mucosa from subjects without pathological reflux [11]. Subsequent research found that miR-143, miR-145, miR-192, and miR-194 were also significantly increased in esophageal epithelial cells (Het-1A) upon acidic bile salt stimulation [12]. miR-203 and miR-205 are high in normal squamous epithelium and low in
miR-203 expression levels were evaluated by qRT-PCR in patients with GERD (n = 142) and Ctrl (n = 48). The median level of expression is represented in each group by a solid line. The values are normalized to U6 expression levels and displayed in log 10 scale on Y-axis.

To the best of our knowledge, tongue coating miRNAs have not been previously compared between GERD patients and Ctrls. In this study, we hypothesised that miR-143, miR-145, miR-192, miR-194, miR-203, and miR-205 expression might be altered in tongue coating in response to chronic gastroesophageal reflux. Therefore, we evaluated these six miRNA expression levels from the tongue coating in patients with GERD and Ctrls. qRT-PCR results demonstrated that six miRNAs can be found in exfoliated cells of the tongue coating in patients with GERD and Ctrls. miR-203 in exfoliated cells of the tongue coating was significantly downregulated in GERD patients as compared with Ctrls (P < 0.0001) with ROC curve areas of 0.94 (95% CI: 0.90–0.97) and a sensitivity and specificity of 91.7% and 87.3%, respectively, in the GERD subjects and Ctrls. These results suggest that the expression level of miR-203 may be a useful marker for discriminating GERD from Ctrls, with the advantage that this technique is noninvasive and inexpensive.

Studies interrogating the expression of miR-203 have suggested that high-level expression is observed in skin and in the esophagus, an organ sharing anatomical similarities with skin [14]. Similarly, in performing whole mouse embryo in situ hybridization, Yi et al. detected miR-203 signal in the epidermis and the tongue [15]. miR-203 expression has been shown to be dysregulated in several malignancies, including gastric cancer, esophageal cancer, lung cancer, squamous cell carcinoma, and cervical cancer [16–20]. miR-203 is significantly downregulated in Barrett’s esophagus (BE) and was also reduced for comparisons of Barrett’s high grade dysplasia (HGD), or esophageal adenocarcinoma (EAC) tissues as compared to that in esophageal mucosa in several studies [21, 22]. Our study demonstrated that miR-203 in exfoliated cells of the tongue coating was significantly downregulated in GERD patients as compared with Ctrls.

This finding suggests that gastroesophageal reflux alters the expression of miRNAs, including miR-203, identified in our study, in exfoliated cells of the tongue coating. We speculate that, after appropriate validation, this noninvasive test can be used to improve diagnosis of GERD and predict indirectly the efficacy of different treatment methods used for controlling GERD. These miRNAs including miR-203 could target genes and pathways that may contribute to GERD pathogenesis; however, the specific molecular mechanism remains to be determined and awaits further investigation.

Recently, miR-203 has been indicated to play a key role in the regulation of normal immunity or inflammation response [23, 24]. However, we found no difference in miR-203 expression in exfoliated cells of the tongue between GERD patients with inflamed and uninflamed esophageal mucosa.

Our study has some limitations. Most of the GERD patients had a grade of A and B, 62%, 25%, respectively. No difference was found in miR-203 expression between the patients with grades A and B. Another limitation was the failure to recruit patients with non-GERD-related disease. Moreover, as global miRNA expression changes were not assessed, it is possible that the expression of other miRNAs may be altered in response to chronic reflux.

In summary, we demonstrated that miR-203 was significantly downregulated in exfoliated cells of the tongue coating in patients with GERD. We suggest that miR-203 testing may assist in the diagnosis of patients with symptoms suggestive of GERD. This may lessen the use of unnecessary antireflux therapy and the need for further invasive and expensive diagnostic methods. Nevertheless, this approach should be further validated in larger cohorts of patients, especially those with non-GERD-related disease, to assess their efficacy and potential applicability in a screening setting.

### Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
Authors’ Contributions

Hui Zhang and Shengliang Zhu conceived this study. Xiuli Yan and Hui Zhang collected and analyzed data. Xiuli Yan and Hui Zhang composed the paper. All of the authors have read the paper and gave final approval for publication.

Acknowledgments

This work was supported by grant from the National Natural Science Foundation of China (no. 81373518).

References

[1] X. J. Yang, H. M. Jiang, X. H. Hou, and J. Song, “Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life,” World Journal of Gastroenterology, vol. 21, no. 14, pp. 4302–4309, 2015.
[2] J. O. Hayat, S. Gabieta-Somnez, E. Yazaki et al., “Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease,” Gut, vol. 64, no. 3, pp. 373–380, 2015.
[3] B. Jiang, X. Liang, Y. Chen et al., “Integrating next-generation sequencing and traditional tongue diagnosis to determine tongue coating microbiome,” Scientific Reports, vol. 2, p. 936, 2012.
[4] Z. M. Sun, J. Zhao, P. Qian et al., “Metabolic markers and microecological characteristics of tongue coating in patients with chronic gastritis,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, p. 227, 2013.
[5] S. Han, Y. Chen, J. Hu, and Z. Ji, “Tongue images and tongue coating microbiome in patients with colorectal cancer,” Microbial Pathogenesis, vol. 77, pp. 1–6, 2014.
[6] N. I. Hornick, J. Huang, B. Doron et al., “Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML,” Scientific Reports, vol. 5, Article ID 11295, 2015.
[7] J. Zhou, G. Gong, H. Tan et al., “Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma,” Oncology Reports, vol. 33, no. 6, pp. 2915–2923, 2015.
[8] F. Wang, J. F. Lou, Y. Cao et al., “miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy,” Experimental & Molecular Medicine, vol. 47, article e162, 2015.
[9] J. Zhang, Y. Song, C. Zhang et al., “Circulating MiR-16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer,” Theranostics, vol. 5, no. 7, pp. 733–745, 2015.
[10] B. P. L. Wijnhoven, D. J. Hussey, D. J. Watson, A. Tsykin, C. M. Smith, and M. Z. Michael, “MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma,” British Journal of Surgery, vol. 97, no. 6, pp. 853–861, 2010.
[11] C. M. Smith, M. Z. Michael, D. I. Watson et al., “Impact of gastro-oesophageal reflux on microRNA expression, location and function,” BMC Gastroenterology, vol. 13, no. 1, article 4, 2013.
[12] P. Bus, P. D. Siersema, R. E. Verbeek, and J. W. P. M. van Baal, “Upregulation of miRNA-143, -145, -192, and -194 in esophageal epithelial cells upon acidic bile salt stimulation,” Diseases of the Esophagus, vol. 27, no. 6, pp. 591–600, 2014.
[13] R. Mallick, S. K. Patnaik, S. Wani, and A. Bansal, “A systematic review of esophageal microRNA markers for diagnosis and monitoring of Barrett’s oesophagus,” Digestive Diseases and Sciences, vol. 61, no. 4, pp. 1039–1050, 2016.
[14] E. Sonkoly, T. Wei, P. C. J. Janson et al., “MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?” PLoS ONE, vol. 2, no. 7, Article ID e610, 2007.
[15] R. Yi, M. N. Poy, M. Stoffel, and E. Fuchs, “A skin microRNA promotes differentiation by repressing ‘stemness’,” Nature, vol. 452, no. 7184, pp. 225–229, 2008.
[16] X. Zhou, G. Xu, C. Yin, W. Jin, and G. Zhang, “Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK,” Oncotarget, vol. 5, no. 22, pp. 11631–11640, 2014.
[17] F. Zhang, Z. Yang, M. Cao et al., “MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer,” Cancer Letters, vol. 342, no. 1, pp. 121–129, 2014.
[18] N. Wang, H. Liang, Y. Zhou et al., “miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC,” PLoS ONE, vol. 9, no. 8, Article ID e105570, 2014.
[19] L. Tian, M. Li, J. Ge et al., “MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours,” Tumor Biology, vol. 35, no. 6, pp. 5953–5963, 2014.
[20] X. Zhu, K. Er, C. Mao et al., “miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer,” Cellular Physiology and Biochemistry, vol. 32, no. 1, pp. 64–73, 2013.
[21] J. Gu, Y. Wang, and X. Wu, “MicroRNA in the pathogenesis and prognosis of esophageal cancer,” Current Pharmaceutical Design, vol. 19, no. 7, pp. 1292–1300, 2013.
[22] O. Slaby, J. Srovnal, L. Radova et al., “Dynamic changes in microRNA expression profiles reflect progression of Barrett’s esophagus to esophageal adenocarcinoma,” Carcinogenesis, vol. 36, no. 5, pp. 521–527, 2015.
[23] M. N. Primo, R. O. Bak, B. Schibler, and J. G. Mikkelsen, “Regulation of pro-inflammatory cytokines TNFα and IL24 by microRNA-203 in primary keratinocytes,” Cytokine, vol. 60, no. 3, pp. 741–748, 2012.
[24] Z. Yang, L. Zhong, S. Zhong, R. Xian, and B. Yuan, “miR-203 protects microglia mediated brain injury by regulating inflammatory responses via feedback to MyD88 in ischemia,” Molecular Immunology, vol. 65, no. 2, pp. 293–301, 2015.